UNSPSC 51191579: Mersalyl sodium

This classification denotes a diuretic with the molecular formula C13H15HgNO5.Na.HO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5X1IO031V8, chemically known as mercury, 3-(alpha-carboxy-o-anisamido)-2-methoxypropyl hydroxy-, monosodium salt but more generally known as mersalyl, which bears US NIH Compound Identifier 10293. European Medicines Agency schedules Mersalyl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08779MIG. The term MERSALYL is an International Non-Proprietary Name.

UNSPSC 51191579 Mersalyl sodium is a Commodity code that in recent state and local procurement activity frames water-treatment chemicals and pharmaceutical supplies rather than mersalyl sodium itself. State and local governments procure under this code for chemical inputs to water pollution control operations and for generic multi-source pharmaceuticals and over-the-counter products distributed across public health and human services facilities. The issuing bodies span municipal water departments, state procurement offices, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions and states. The City of Meriden, Connecticut and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represent the mix of single-jurisdiction and regional cooperative buyers active under the code.

Recent activity shows concentration in the upper Midwest and Northeast. The City of Meriden issued IFB B027-15 for sodium bisulfite chemical supply to its Water Pollution Control Facility with bids due July 29, 2026. MMCAP issued RFP S1070000015802 on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products for distribution across participating state and local government facilities in Minnesota, Oregon, and other member states, with awarded vendors required to supply through authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC, and with products becoming available May 15, 2026 and contracts effective July 1, 2026. Vendors responding to MMCAP must certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintain relationships with at least two of three authorized wholesalers, and carry commercial general liability of $5,000,000 per occurrence and network security and privacy liability of $2,000,000.